Loading provider…
Loading provider…
Hematology & Oncology Physician in Richmond, VA
NPI: 1205887270Primary Practice Location
MEDICAL COLLEGE OF VIRGINIA HOSPITALS
1213 E Clay St, Richmond, VA
Primary Employer
MCV Associated Physicians
vcuhealth.org
HQ Phone
Get MD Bruce's Phone NumberMobile
Get MD Bruce's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardVA State Medical License
FL State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 95 | 127 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 77 | 129 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 34 | 34 |
| 4 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 24 | 76 |
| 5 | 99204New patient office or other outpatient visit, 45-59 minutes | 18 | 18 |
Authors: Yoshihiro Komatsu, Astha Bhatt, Usha Malhotra, Toshitaka Hoppo
Journal: Ann Surg
New and developing first line pharmacotherapies for treating non-Hodgkin lymphoma.
Authors: Victor Yazbeck, Patrick Willard, Ariel Sindel
Journal: Expert Opin Pharmacother
Publication Date: 2024-08-21
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, DRUG: Sunitinib Malate, BIOLOGICAL: Nivolumab, OTHER: Laboratory Biomarker Analysis, DRUG: Osimertinib, PROCEDURE: Biospecimen Collection, DRUG: Dabrafenib, DRUG: Crizotinib, DRUG: Sapanisertib, DRUG: Taselisib, PROCEDURE: Computed Tomography, BIOLOGICAL: Trastuzumab, DRUG: Trametinib, PROCEDURE: Multigated Acquisition Scan, DRUG: Palbociclib, DRUG: Afatinib, DRUG: Ulixertinib, OTHER: Cytology Specimen Collection Procedure, DRUG: Dasatinib, DRUG: Vismodegib, DRUG: Afatinib Dimaleate, DRUG: Adavosertib, PROCEDURE: Biopsy Procedure, DRUG: Defactinib, PROCEDURE: Radionuclide Imaging, BIOLOGICAL: Trastuzumab Emtansine, DRUG: Copanlisib, PROCEDURE: Echocardiography Test, DRUG: PI3K-beta Inhibitor GSK2636771, DRUG: Larotrectinib, BIOLOGICAL: Relatlimab, DRUG: Copanlisib Hydrochloride, DRUG: Capivasertib, DRUG: Erdafitinib, DRUG: Larotrectinib Sulfate, DRUG: Binimetinib, BIOLOGICAL: Pertuzumab, DRUG: Ipatasertib, DRUG: Dabrafenib Mesylate, DRUG: Defactinib Hydrochloride, DRUG: Fexagratinib, PROCEDURE: Radiologic Examination
Lead Sponsor: NRG Oncology
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Carboplatin, OTHER: Laboratory Biomarker Analysis, DRUG: Cyclophosphamide, DRUG: Paclitaxel, DRUG: Doxorubicin Hydrochloride